ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY

被引:10
|
作者
Roberts, Megan C. [1 ,2 ]
Bryson, Amy [3 ]
Weinberger, Morris [1 ,4 ]
Dusetzina, Stacie B. [1 ,2 ,5 ]
Dinan, Michaela A. [6 ,7 ]
Reeder-Hayes, Katherine [2 ,8 ]
Wheeler, Stephanie B. [1 ,2 ]
机构
[1] UNC, Gillings Sch Global Publ Hlth, Hlth Policy Management, Chapel Hill, NC 27514 USA
[2] UNC, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27514 USA
[3] UNC, Gillings Sch Global Publ Hlth, Hlth Behav, Chapel Hill, NC USA
[4] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res, Durham, NC USA
[5] UNC Eshelman Sch Pharm, Div Pharmaceut Outcomes & Policy, Chapel Hill, NC USA
[6] Duke Univ, Duke Clin Res Inst, Durham, NC 27706 USA
[7] Duke Univ, Duke Canc Inst, Durham, NC 27706 USA
[8] UNC, Div Hematol Oncol, Chapel Hill, NC USA
基金
美国医疗保健研究与质量局; 美国国家卫生研究院;
关键词
Breast cancer; Gene expression profiling; Qualitative research; RECURRENCE SCORE ASSAY; STAGE BREAST-CANCER; GENE-EXPRESSION; RISK; WOMEN; RECOMMENDATIONS;
D O I
10.1017/S026646231600060X
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Oncotype DX (ODX), a tumor gene profiling test, has been incorporated into clinical guidelines to aid in adjuvant chemotherapy decision making for early-stage, hormone receptor positive breast cancer patients. Despite United States (U.S.) guidelines, less than half of eligible women receive testing. Reasons for low usage are unclear: Our objective was to better understand U.S. oncologists' ODX uptake and how they use ODX during adjuvant chemotherapy decision making. Methods: We conducted semi-structured, similar to 30-minute phone interviews with medical and surgical oncologists in one U.S. State using purposive sampling. Oncologists were included if they saw greater than or equal to five breast cancer patients per week. Recruitment ended upon thematic saturation. Interviews were recorded, transcribed, and double-coded using template analysis. Results: During analysis, themes emerged across three domains. First, organizational factors (i.e., departmental structure, ODX marketing, and medical/insurance guidelines) influenced ease of ODX use. Second, oncologists referenced the influence of interpersonal factors (e.g., normative beliefs and peer use of ODX) over their own practices and recommendations. Third, intrapersonal factors (e.g., oncologist attitudes, perceived barriers, and research gaps) were discussed: although oncologists largely held positive attitudes about ODX, they reported challenges with interpreting intermediate scores for treatment decisions and explaining test results to patients. Finally, oncologists identified several research gaps. Conclusions: As more tumor gene profiling tests are incorporated into cancer care for treatment decision making, it is important to understand their use in clinical practice. This study identified multi-level factors that influence ODX uptake into clinical practice, providing insights into facilitators and modifiable barriers that can be leveraged for improving ODX uptake to aid treatment decision making.
引用
收藏
页码:355 / 361
页数:7
相关论文
共 50 条
  • [41] Barriers and facilitators to primary care for people with mental health and/or substance use issues: a qualitative study
    Lori E. Ross
    Simone Vigod
    Jessica Wishart
    Myera Waese
    Jason Dean Spence
    Jason Oliver
    Jennifer Chambers
    Scott Anderson
    Roslyn Shields
    BMC Family Practice, 16
  • [42] Barriers and Facilitators to Harm Reduction for Opioid Use Disorder: A Qualitative Study of People With Lived Experience
    Westafer, Lauren M.
    Beck, Samantha A.
    Simon, Caty
    Potee, Benjamin
    Soares, William E.
    Schoenfeld, Elizabeth M.
    ANNALS OF EMERGENCY MEDICINE, 2024, 83 (04) : 340 - 350
  • [43] Barriers and facilitators to primary care for people with mental health and/or substance use issues: a qualitative study
    Ross, Lori E.
    Vigod, Simone
    Wishart, Jessica
    Waese, Myera
    Spence, Jason Dean
    Oliver, Jason
    Chambers, Jennifer
    Anderson, Scott
    Shields, Roslyn
    BMC FAMILY PRACTICE, 2015, 16
  • [44] Barriers and Facilitators to Seek Help for Substance Use Disorder among Dutch Physicians: A Qualitative Study
    Geuijen, Pauline M.
    Pars, Esther
    Kuppens, Joanneke M.
    Schene, Aart H.
    de Haan, Hein A.
    de Jong, Cornelis A. J.
    Atsma, Femke
    Schellekens, Arnt F. A.
    EUROPEAN ADDICTION RESEARCH, 2022, 28 (01) : 23 - 32
  • [46] Barriers and Facilitators to the Use of Wearable Robots as Assistive Devices: Qualitative Study With Older Adults and Physiotherapists
    Reicherzer, Leah
    Scheermesser, Mandy
    Klay, Adrian
    Duarte, Jaime E.
    Graf, Eveline S.
    JMIR REHABILITATION AND ASSISTIVE TECHNOLOGIES, 2024, 11
  • [47] Barriers and Facilitators to Chlorine Tablet Distribution and Use in Emergencies: A Qualitative Assessment
    Mitro, Brittany
    Wolfe, Marlene K.
    Galeano, Mateo
    Sikder, Mustafa
    Gallandat, Karin
    Lantagne, Daniele
    WATER, 2019, 11 (06)
  • [48] Facilitators and Barriers to Antibiotic Stewardship: A Qualitative Study of Pharmacists' Perspectives
    Appaneal, Haley J.
    Luther, Megan K.
    Timbrook, Tristan T.
    LaPlante, Kerry L.
    Dosa, David M.
    HOSPITAL PHARMACY, 2019, 54 (04) : 250 - 258
  • [49] A Qualitative Study of Facilitators and Barriers to Self-Management of CKD
    Schrauben, Sarah J.
    Rivera, Eleanor
    Bocage, Claire
    Eriksen, Whitney
    Amaral, Sandra
    Dember, Laura M.
    Feldman, Harold, I
    Barg, Frances K.
    KIDNEY INTERNATIONAL REPORTS, 2022, 7 (01): : 46 - 55
  • [50] Perceptions of barriers and facilitators to engaging in implementation science: a qualitative study
    Stevens, E. R.
    Shelley, D.
    Boden-Albala, B.
    PUBLIC HEALTH, 2020, 185 : 318 - 323